The purpose of this study was to investigate patient reactions and understanding of secondary genomic findings with limited to no medical actionability (LMA-SFs) from diagnostic genome sequencing. Gail E. Henderson, PhD, analyzed LMA-SFs returned to 47 adults who elected to receive a broad set of these results from six categories.
Most participants received some reportable LMA-SFs for common risk, pharmacogenetic, and carrier status variants. Participants’ short-term well-being was not reduced by receiving LMA-SFs. Their interpretations suggested varied personal utilities and the need for post-test resources to aid understanding of these types of results and their health significance.